# Future Medicine Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/future-medicine-co

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.futuremedicine.co.kr
- Total disclosed funding: $17M
- Latest round: Series C (Mar 30, 2020)
- Investors on record: 7

## About

Based in South Korea, Future Medicine Co., Ltd. focuses on innovative drug discovery and development, addressing unmet medical needs through its proprietary Nucleoside Library Platform and advancing various therapeutic areas.Founded in 2015 and headquartered in Seongnam, South Korea, Future Medicine Co., Ltd. specializes in drug development leveraging its proprietary technologies. The company has conducted 8 significant deals, with its most recent funding round, PIPE, completed in July 2022, raising KRW 4,050.000 mn from investors including Dreamstone Partners, LSK Investment, and Magna Investment. CEO TJ Song leads the organization, steering its strategic initiatives and operations.Future Medicine specializes in innovative drug discoveries based on its proprietary Nucleoside Library Platform, targeting unmet medical needs in areas such as non-alcoholic fatty liver disease and oncology. Their drug development pipeline encompasses several phases, including pre-clinical and Phase 2 studies, aimed at providing novel treatments with unique mechanisms of action for patients. The company collaborates with various pharmaceutical firms for research and clinical trials, expanding its reach within the global healthcare market. Future Medicine's products are directed towards hospitals, clinics, and research institutions to address critical healthcare challenges primarily within the Asia-Pacific region and potentially extending to global markets.Future Medicine's revenue model is structured around collaborations and partnerships within the biopharmaceutical sector, particularly through clinical trial agreements and technology licensing arrangements. It raised no revenue in 2022, with an EBITDA of -KRW 2,975,452.80. The company is pursuing an initial public offering (IPO) to enhance its operational capacity and research investments.Future Medicine is focused on expanding its product offerings and geographical reach. Following the IPO completed in July 2022, where it raised KRW 4,050.000 mn selling 9.28 million shares on the KONEX stock exchange, the company plans to allocate these funds towards advancing its drug development pipeline and entering new markets. Specific regions targeted for expansion include additional countries in the Asia-Pacific area and global markets, aligning with their strategic growth objectives.

## Funding rounds

- Series C, Mar 30, 2020, $5.3M — Korea Investment & Securities, BNK Venture Capital, Hanwha Investment & Securities, HK Inno.N Corporation
- Series B, Apr 4, 2019, $6.2M — Kolon Investment, NH Investment & Securities, Wooshin Venture Capital
- Series A, Jul 28, 2018, $5.5M — Kolon Investment, Wooshin Venture Capital

## Investors

- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A, Series B
- Wooshin Venture Capital (https://capitalatlas.ai/funds/wooshin-venture-capital) — Series A, Series B
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series B
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series C
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series C
- Hanwha Investment & Securities (https://capitalatlas.ai/funds/hanwha-investment-securities) — Series C
- HK Inno.N Corporation — Series C